PDS Biotechnology Corporation (NASDAQ: PDSB) filed an amendment to its VERSATILE-003 Phase 3 clinical trial protocol that incorporates progression-free survival ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE